Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis

Moreno, Christophe; Deltenre, Pierre; Pawlotsky, Jean‐Michel; Henrion, Jean; Adler, Michaël; Mathurin, Philippe

doi:10.1016/j.jhep.2009.10.003

Cited by 61 publications

(49 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HVY alınan ve başlangıçtaki HCV RNA düzeyi düşük olan (<800 000 İÜ/ml) hastalarda tedavi 24 haftada kesilebilir. Geç viral yanıt veren hastalarda tedavi süresi 72 haftaya kadar uzatılabilir (113)(114)(115)(116)(117)(118)(119). Öneriler 1.…”

Section: Genotip 1 Ile İnfekte Naif Hastalarda İkili Tedavinin Yeriunclassified

Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Aygen¹,

Keten²,

Akalın³

et al. 2015

Klimik Dergisi

View full text Add to dashboard Cite

ÖzetTürk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu, dünyada yaklaşık olarak 170 milyon kişide bulunan kronik hepatit C virusu (HCV) infeksiyonunun yönetimine ilişkin bir uzlaşı raporu hazırlamak üzere bir toplantı düzenlemiştir. Raporda konuyla ilgili literatür ve uluslararası kılavuzlar, HCV infeksiyonunun epidemiyolojisi ve doğal seyri, kronik hepatit C (KHC)'nin ülke ekonomisine maliyeti, akut hepatit C (AHC) ve KHC tanısı, AHC tedavisi, KHC'de tedavinin amaçları, tedavi yanıtlarının tanımları, tedavinin sonlandırılma AbstractStudy Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases convened a meeting to develop a consensus report on management of chronic hepatitis C virus (HCV) infection, a global public health problem, affecting nearly 170 million people worldwide. Relevant literature and international guidelines were reviewed, and recommendations agreed are presented at the end of each section such as epidemiology and natural history of HCV infection, economic burden of chronic hepatitis C (CHC), diagnosis of acute hepatitis

show abstract

Section: Genotip 1 Ile İnfekte Naif Hastalarda İkili Tedavinin Yeriunclassified

Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Aygen¹,

Keten²,

Akalın³

et al. 2015

Klimik Dergisi

View full text Add to dashboard Cite

show abstract

“…9,77 In East Asian HCV-1 patients who achieved RVR, two independent studies indicated that the SVR rate for 24 weeks of PEG-IFN α-2a plus RBV therapy is similar to 48 weeks of combination therapy in HCV-1 patients with baseline viral load ,400,000 IU/mL (94%-96% vs 100%, respectively). 53,54 In contrast, patients who failed to achieve RVR or patients who achieved RVR but had high viral load (.400,000-800,000 IU/mL) should receive 48 weeks of therapy to secure the SVR rates.…”

Section: Response-guided Therapy For Asian Patients With Chronic Hcv mentioning

confidence: 99%

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa

Liu¹,

Kao

2014

IJN

View full text Add to dashboard Cite

Asia is endemic for hepatitis C virus (HCV) infection, which is the leading cause of cirrhosis, hepatic decompensation, hepatocellular carcinoma, and liver transplantation worldwide. HCV has six major genotypes and each HCV genotype has its specific geographic distribution. HCV genotypes 1, 2, 3, and 6 are common in Asia. The aim of HCV treatment is to eradicate the virus by effective therapeutic agents; viral clearance is durable after long-term post-treatment follow-up. In most Asian countries, peginterferon alfa (PEG-IFN α) in combination with ribavirin remains the standard of care, and the overall sustained viral response (SVR) rate in Asian HCV patients is higher than that in Western patients. The differences are most significant in patients with HCV genotype 1 (HCV-1) infection, which is attributed to the higher frequency of IFN-responsive or favorable interleukin-28B (IL-28B) genotype in Asian populations than in other ethnic populations. In addition, the introduction of response-guided therapy, where the optimized treatment duration is based on the early viral kinetics during the first 12 weeks of treatment, increases the SVR rate. Recently, telaprevir or boceprevir-based triple therapy was found to further improve the SVR rate in treated and untreated HCV-1 patients and has become the new standard of care in Western and some Asian countries. Many novel direct-acting antiviral agents, either in combination with PEG-IFN α plus ribavirin or used as IFN-free regimens are under active investigation. At the time of this writing, simeprevir and sofosbuvir have been approved in the US. Because the SVR rates in Asian HCV patients receiving PEG-IFN α plus ribavirin therapy are high, health care providers should judiciously determine the clinical usefulness of these novel agents on the basis of treatment duration, anticipated viral responses, patient tolerance, financial burdens, and drug accessibility.

show abstract

“…Bolesnici inficirani HCV genotipom 1, koji postižu rapidni virusološki odgovor (negativan nalaz HCV rnK posle četiri nedelje terapije) i nisku bazalnu viremiju (< 800.000 iu/ml), leče se 24 nedelje. Pacijenti sa visokom bazalnom viremijom leče se 48 nedelja (24)(25)(26)(27). ranim virusološkim odgovorom (Early Viral response -EVr) smatra se pad viremije za bar dva logaritma od početnih vrednosti i ocenjuje se nakon 12 nedelja terapije.…”

Section: Uvodunclassified

“…u zavisnosti od prisustva kofaktora (zloupotreba alkohola, šećerna bolest, stariji uzrast bolesnika, koinfekcija sa HiV i/ili drugim primarno hepatotropnim virusima), 10-50% pacijenata sa hroničnim hepatitisom C dobiće cirozu jetre (27). Smrtni ishod od hronične HCV infekcije i ciroze dešava se u približno 4% slučajeva godišnje, dok se hepatocelularni karcinom (HCC) javlja kod oko 1-5% inficiranih godišnje (42).…”

Section: Diskusijaunclassified

“…dobijeni rezultati takođe pokazuju da u ispitivanoj grupi bolesnika, postoji statistički značajna razlika u zastupljenosti genotipova. naime, najzastupljeniji je genotip 1, koji je utvrđen kod gotovo dve trećine ispitanika, genotip 3 je zastupljen sa jednom trećinom, dok su genotipovi 4 i 2 zastupljeni sa nekoliko procenata, što je u skladu s nekim drugim istraživanja iz ove oblasti (10,(25)(26)(27). Kada je oštećenje jetre u pitanju, u ispitivanoj grupi fibroza prvog stepena procentualno je dominantna, ima je nešto manje od polovine ispitanika, dok je fibroza četvrtog stepena na začelju sa nekoliko procenata.…”

Section: Diskusijaunclassified

See 1 more Smart Citation

10.5937/mckg48-5925 = Therapy of chronic HCV infection: Association between virological response and predictive factors

Vuković¹,

Mijailović²,

Popović³

et al. 2014

Medicinski casopis

View full text Add to dashboard Cite

show abstract

Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis

Cited by 61 publications

References 29 publications

Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa

10.5937/mckg48-5925 = Therapy of chronic HCV infection: Association between virological response and predictive factors

Contact Info

Product

Resources

About